Biotech | July 10, 2022
WuXi XDC and AbTis sign MoU for manufacturing of antibody drug conjugates
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Brings 25 years of global operations and supply chain experience to Piramal
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Company hires life science veteran Jessica Cao to join management team
Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead
New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
Subscribe To Our Newsletter & Stay Updated
